Skip navigation

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

URL of this page:

LHCGR gene

luteinizing hormone/choriogonadotropin receptor

Normal Function

The LHCGR gene provides instructions for making a receptor protein called the luteinizing hormone/chorionic gonadotropin receptor. Receptor proteins have specific sites into which certain other proteins, called ligands, fit like keys into locks. Together, ligands and their receptors trigger signals that affect cell development and function.

The protein produced from the LHCGR gene acts as a receptor for two ligands: luteinizing hormone and a similar hormone called chorionic gonadotropin. The receptor allows the body to respond appropriately to these hormones. In males, chorionic gonadotropin stimulates the development of cells in the testes called Leydig cells, and luteinizing hormone triggers these cells to produce androgens. Androgens, including testosterone, are the hormones that control male sexual development and reproduction. In females, luteinizing hormone triggers the release of egg cells from the ovaries (ovulation); chorionic gonadotropin is produced during pregnancy and helps maintain conditions necessary for the pregnancy to continue.

Health Conditions Related to Genetic Changes

Familial male-limited precocious puberty

At least 17 LHCGR gene mutations have been identified in boys and men with familial male-limited precocious puberty. These mutations replace single protein building blocks (amino acids) in the luteinizing hormone/chorionic gonadotropin receptor. The mutations cause the receptor to be constantly turned on (constitutively activated), even when not attached (bound) to luteinizing hormone or chorionic gonadotropin. Researchers suggest that the change in amino acid sequence may lead to constitutive activation by changing the shape or other properties of the receptor.

In males, the overactive receptor causes the Leydig cells to produce an excess of testosterone, leading to familial male-limited precocious puberty. Affected boys begin exhibiting the signs of puberty, such as genital growth and pubic hair, between the ages of 2 and 5. The overactive receptor has no apparent effect on females.

More About This Health Condition

Leydig cell hypoplasia

LHCGR gene mutations that cause Leydig cell hypoplasia disrupt luteinizing hormone/chorionic gonadotropin receptor function, impeding the body's ability to react to these hormones. In males, the mutations result in poorly developed or absent Leydig cells and impaired production of testosterone. A lack of testosterone interferes with the development of male reproductive organs before birth and the changes that appear at puberty.

Mutations that prevent the production of any functional receptor protein cause more severe signs and symptoms of Leydig cell hypoplasia. Affected individuals with a typical male chromosome pattern (46,XY) have female external genitalia and small testes that are undescended, which means they are abnormally located in the pelvis, abdomen, or groin. Severely affected individuals do not develop secondary sex characteristics, such as increased body hair, at puberty.

LHCGR gene mutations that allow some receptor protein function cause milder signs and symptoms of Leydig cell hypoplasia. Affected males may have a range of genital abnormalities, including a small penis (micropenis), the opening of the urethra on the underside of the penis (hypospadias), or a scrotum divided into two lobes (bifid scrotum). Because of these abnormalities, the external genitalia may not look clearly male or clearly female.

More About This Health Condition

Polycystic ovary syndrome

MedlinePlus Genetics provides information about Polycystic ovary syndrome

More About This Health Condition

Other disorders

Although people who are genetically female (with two X chromosomes in each cell) may inherit mutations in both copies of the LHCGR gene that disrupt luteinizing hormone/chorionic gonadotropin receptor function, they do not have Leydig cell hypoplasia because they do not have Leydig cells. Females with the same LHCGR gene mutations that cause Leydig cell hypoplasia in males have normal female genitalia and normal breast and pubic hair development, but they may begin menstruation later than usual (after age 16) and have irregular menstrual periods. These mutations also prevent ovulation, leading to an inability to have children (infertility).

Other Names for This Gene

  • FLJ41504
  • HHG
  • LCGR
  • LGR2
  • LH/CG-R
  • LH/CGR
  • LHR
  • LSH-R
  • luteinizing hormone/choriogonadotropin receptor precursor
  • lutropin/choriogonadotropin receptor
  • ULG5

Additional Information & Resources

Tests Listed in the Genetic Testing Registry

Scientific Articles on PubMed

Catalog of Genes and Diseases from OMIM

Gene and Variant Databases


  • Kossack N, Simoni M, Richter-Unruh A, Themmen AP, Gromoll J. Mutations in a novel, cryptic exon of the luteinizing hormone/chorionic gonadotropin receptor gene cause male pseudohermaphroditism. PLoS Med. 2008 Apr 22;5(4):e88. doi: 10.1371/journal.pmed.0050088. Citation on PubMed or Free article on PubMed Central
  • Qiao J, Han B, Liu BL, Chen X, Ru Y, Cheng KX, Chen FG, Zhao SX, Liang J, Lu YL, Tang JF, Wu YX, Wu WL, Chen JL, Chen MD, Song HD. A splice site mutation combined with a novel missense mutation of LHCGR cause male pseudohermaphroditism. Hum Mutat. 2009 Sep;30(9):E855-65. doi: 10.1002/humu.21072. Citation on PubMed
  • Themmen AP, Verhoef-Post M. LH receptor defects. Semin Reprod Med. 2002 Aug;20(3):199-204. doi: 10.1055/s-2002-35384. Citation on PubMed
  • Wu SM, Chan WY. Male pseudohermaphroditism due to inactivating luteinizing hormone receptor mutations. Arch Med Res. 1999 Nov-Dec;30(6):495-500. doi: 10.1016/s0188-4409(99)00074-0. Citation on PubMed
  • Wu SM, Leschek EW, Rennert OM, Chan WY. Luteinizing hormone receptor mutations in disorders of sexual development and cancer. Front Biosci. 2000 Mar 1;5:D343-52. doi: 10.2741/wu. Citation on PubMed

The information on this site should not be used as a substitute for professional medical care or advice. Contact a health care provider if you have questions about your health.